Description

TERBIFACE 250 MG

Indications

TERBIFACE 250 MG is a pharmaceutical preparation primarily indicated for the treatment of fungal infections. It is effective against dermatophytes, yeasts, and some molds. Common conditions treated with TERBIFACE include tinea pedis (athlete’s foot), tinea corporis (ringworm), tinea cruris (jock itch), and onychomycosis (fungal nail infections). The medication is often prescribed for patients who have not responded adequately to topical antifungal therapies.

Mechanism of Action

TERBIFACE contains terbinafine as its active ingredient, which belongs to the class of antifungal agents known as allylamines. The primary mechanism of action of terbinafine involves the inhibition of squalene epoxidase, an enzyme crucial for the biosynthesis of ergosterol, a vital component of fungal cell membranes. By disrupting the formation of ergosterol, terbinafine leads to increased permeability of the fungal cell membrane, ultimately resulting in cell lysis and death of the fungus. This action is effective against a broad spectrum of dermatophytes and some non-dermatophyte fungi.

Pharmacological Properties

TERBIFACE is well-absorbed when administered orally, with peak plasma concentrations typically occurring within 2 hours. The drug has a high volume of distribution, indicating extensive tissue binding, particularly in skin and nail tissues, where it exerts its antifungal effects. Terbinafine is primarily metabolized by the liver, and its elimination half-life ranges from 25 to 35 hours, allowing for once-daily dosing in most cases. The drug is excreted mainly through urine, with a small percentage eliminated in feces.

Contraindications

TERBIFACE is contraindicated in patients with a known hypersensitivity to terbinafine or any of the excipients in the formulation. It should not be used in individuals with severe liver disease or active liver dysfunction, as terbinafine is extensively metabolized by the liver and may exacerbate hepatic impairment. Additionally, caution is advised in patients with a history of systemic lupus erythematosus or those undergoing immunosuppressive therapy.

Side Effects

While TERBIFACE is generally well-tolerated, some patients may experience side effects. Common side effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain. Dermatological reactions such as rashes, pruritus, and urticaria may also occur. Rare but serious side effects include hepatotoxicity, which may manifest as jaundice, elevated liver enzymes, or hepatic failure. Other rare adverse effects include neutropenia and allergic reactions. Patients should be monitored for any signs of liver dysfunction, especially during prolonged therapy.

Dosage and Administration

The recommended dosage of TERBIFACE for adults is typically 250 mg taken orally once daily. Treatment duration may vary depending on the type and severity of the fungal infection. For tinea pedis and tinea corporis, a treatment course of 2 to 6 weeks is usually sufficient, while onychomycosis may require treatment for 6 to 12 weeks or longer. It is essential to adhere to the prescribed dosage and duration to ensure effective treatment and minimize the risk of recurrence. Patients should be advised to take the medication with or without food, as food does not significantly affect the absorption of terbinafine.

Interactions

TERBIFACE may interact with several medications, potentially altering their effects or increasing the risk of side effects. Notable interactions include those with CYP450 enzyme inducers or inhibitors. For instance, rifampicin, a potent inducer, may decrease the plasma concentration of terbinafine, reducing its efficacy. Conversely, medications such as cimetidine, which inhibit CYP450 enzymes, may increase terbinafine levels, raising the risk of adverse effects. Patients should inform their healthcare providers of all medications they are taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Prior to initiating treatment with TERBIFACE, a thorough medical history and assessment should be conducted. Special precautions should be taken in patients with pre-existing liver conditions, renal impairment, or a history of blood disorders. Regular monitoring of liver function tests is recommended during therapy, especially for patients receiving long-term treatment. Additionally, TERBIFACE should be used with caution in pregnant or breastfeeding women, as the effects on fetal development and lactation are not fully understood. It is advisable to weigh the potential benefits against the risks before prescribing this medication to these populations.

Clinical Studies

Clinical studies have demonstrated the efficacy of TERBIFACE in treating various fungal infections. In a randomized controlled trial involving patients with onychomycosis, TERBIFACE was shown to be significantly more effective than placebo, with a higher rate of complete cure and mycological eradication. Other studies have confirmed its effectiveness in treating tinea infections, with a favorable safety profile. The results indicate that TERBIFACE not only alleviates symptoms but also addresses the underlying fungal infection, leading to sustained remission in many patients.

Conclusion

TERBIFACE 250 MG is a potent antifungal agent indicated for the treatment of various dermatophyte infections. Its mechanism of action, pharmacological properties, and clinical efficacy make it a valuable option for patients who require systemic antifungal therapy. While generally well-tolerated, it is essential for healthcare providers to monitor patients for potential side effects and drug interactions. By adhering to prescribed dosages and treatment durations, patients can achieve optimal outcomes in managing their fungal infections.